NCT03809286 (MAGNA) is a NA clinical trial of active rTMS in Alcohol Use Disorder, sponsored by New York State Psychiatric Institute.

Who is sponsoring NCT03809286?

NCT03809286 is sponsored by New York State Psychiatric Institute.

What drugs are being tested in NCT03809286?

Interventions in NCT03809286: active rTMS, Inpatient admission, sham rTMS.

What condition does NCT03809286 study?

NCT03809286 studies Alcohol Use Disorder.

Is NCT03809286 still recruiting?

NCT03809286 is currently suspended. Last updated 19 March 2026.

Last reviewed 2026-03-19 · How we verify

NCT03809286: MAGNA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of rTMS to the Prefrontal Cortex in Alcohol Use Disorder

Suspended NA Last updated 19 March 2026

What this trial tests

NA trial testing active rTMS in Alcohol Use Disorder in 44 participants. Suspended.

Timeline

24 June 2019

Primary endpoint
30 December 2026

30 December 2026

Quick facts

Lead sponsor	New York State Psychiatric Institute
Phase	NA
Status	Suspended
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	44
Start date	24 June 2019
Primary completion	30 December 2026
Estimated completion	30 December 2026
Sites	1 location across United States

Drugs / interventions tested

active rTMS
Inpatient admission
sham rTMS

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →

Sponsor

New York State Psychiatric Institute

Who can join

Adults 22 to 55, any sex, with Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to investigate a treatment approach for alcohol use disorder (AUD) using a novel form of brain stimulation called deep repetitive transcranial magnetic stimulation (rTMS). The investigators will be targeting frontal regions of the brain that are important for memory and decision making. These brain regions have been shown to be impaired in patients with AUD. Previous studies have mostly used rTMS to a different frontal brain region that is not as deep. These studies have shown that rTMS can reduce craving for alcohol, but there is a lack of research showing that rTMS impacts alcohol consumption.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

INSPECTOR: free software for magnetic resonance spectroscopy data inspection, processing, simulation and analysis.
Gajdošík M, Landheer K, Swanberg KM, Juchem C. · · 2021 · cited 30× · PMID 33483543 · DOI 10.1038/s41598-021-81193-9

Verify or expand the search:

Other trials of active rTMS

Trials testing the same drug.

NCT06288984 — Effects of rTMS on Respiratory Function and Gut Microbiota in Patients With Brain Injury · NA · not yet recruiting
NCT06095778 — rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS · NA · unknown
NCT05872243 — pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD) · NA · unknown
NCT05976022 — pBFS Guided rTMS Therapy Over Different Targets for Treatment-Resistant Depression · NA · unknown
NCT05850598 — Effect of rTMS of the Cerebellum on Parkinson's Disease · NA · completed

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Other New York State Psychiatric Institute trials

Trials by the same sponsor.

NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03809286 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
Last refreshed: 19 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03809286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing